Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025

Group 1 - The article discusses Neurocrine Biosciences (NASDAQ: NBIX) and highlights a previous analysis regarding a buying opportunity following a stock price drop related to schizophrenia data [2] - The author operates the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and includes a library of over 600 biotech investing articles [2] - The service offers a model portfolio of more than 10 small and mid-cap stocks, along with live chat and various analysis and news reports to assist healthcare investors [2] Group 2 - The article does not contain any specific financial data or performance metrics related to Neurocrine Biosciences or the broader biotech industry [1][3][4]